Company signals · Biotech
Immuneel Therapeutics
3 signals in the current window, with MitchelLake's leadership read on each.
Market context: the MitchelLake Talent Market Index reads 108.5 — Hot; Asia signal share is easing (-2.1pts).
Signals at Immuneel Therapeutics
Product Launch
AsiaImmuneel commercialised Qartemi (CAR-T therapy for Non-Hodgkin Lymphoma) in late 2024 and has treated 100+ patients. Now focusing on expanding to leukemia treatment and advancing solid tumor programs.
Leadership read: Requires Commercial/Sales leadership for Qartemi rollout, Medical Affairs executives, Patient Access/Reimbursement specialists, Clinical Trial Management leads for leukemia and solid tumor programs, and Market Access executives for new indications.
curated · 2026-06-08 · context →
Geographic Expansion
EMEAImmuneel is expanding from India into Asia Pacific, Middle East, Australia, and Southeast Asia with clinical co-development partnerships, and targeting North America and Europe long-term.
Leadership read: Requires Regional VPs/Directors for APAC and MEA, Country Managers for Australia and key SEA markets, International Regulatory Affairs specialists, Partnership Development executives, and Commercial leads with emerging markets experience.
curated · 2026-06-08 · context →
Capital Raising
AsiaBengaluru CAR-T therapy company Immuneel Therapeutics closed a Rs 100+ crore (about US$12 million) Series B with Singularity AMC and Rainmatter joining existing backers including Kiran Mazumdar-Shaw, Eight Roads and F-Prime — funding GMP manufacturing scale-up and Qartemi commercialisation.
Leadership read: Manufacturing and operations scaling leadership, regulatory-affairs leads for Asia-Pacific and Middle East market entry, and commercial executives for India's first approved CAR-T therapy.
curated · 2026-06-08 · context →